A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

Alzheimer Disease Clinical Trial

Official title:

A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03455569
• Other study ID #: 1K23AG055668-03
• Status: Completed
• Phase: N/A
• Start date: September 11, 2018
• Est. completion date: February 1, 2023

Study information

• Verified date: August 2023
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Studies consistently show the negative health impact of sleep problems in both Alzheimer's disease (AD) patients and their caregivers. However, only a few sleep interventions have been conducted for AD patients or their caregivers in community settings and none have addressed both members of the dyad concurrently. To fill these gaps, this study aims to develop a sleep intervention program specifically tailored for AD patient/caregiver dyads who both experience sleep difficulties.

Description:

In 2015, Americans provided 18 billion hours of unpaid care for patients with Alzheimer's disease (AD) and other dementias, with an economic value of $221 billion. This estimate may be even higher among caregivers of AD patients when they have sleep problems. In fact, the caregivers' sleep is often disturbed by nighttime sleep disturbance of AD patients, which is one of the major reasons why those patients are admitted to institutions. Due to the bidirectional nature of sleep disturbance in AD patients and their caregivers, it is critical to develop a sleep intervention program for the dyad that addresses sleep disturbance in both individuals.

Nighttime sleep disturbance in AD patients is associated with shorter survival, lower quality of life, and decreased social engagement. Poor sleep among their caregivers is associated with increased depressive symptoms, higher levels of caregiver role burden, and increased inflammation, which is known to increase risk for cardiovascular disease. Such decline in caregivers' health may then impact the quality of care for AD patients.

Behavioral sleep intervention programs for AD patients or caregivers are feasible but long-term effects on improving sleep and health remain unclear. No behavioral sleep interventions have focused on the patient-caregiver dyad, and only a few behavioral sleep intervention studies have targeted community-dwelling AD patients or caregivers. Dyad-based sleep interventions may have better effects on sleep and other health outcomes because of the influence of AD patients on their caregivers and vice versa.

The proposed intervention focuses on educating caregivers to improve their own and the patients' sleep, using behavioral sleep management techniques. This intervention builds upon a previous caregiver focus group study (VA HSR&D LIP 65-154, PI: Song) and the existing sleep interventional research studies, which included patients with mild cognitive impairments and AD patients. The sleep program involves 4 face-to-face meetings plus 1 telephone session. Phase 1 study aims to iteratively refine and finalize the intervention program materials with 5 AD patient/caregiver dyads. Phase 2 study aims to pilot test the effects of the intervention program (n=20 dyads) on sleep, health, and quality of life in both members of the group, compared to a non-directive education-only control program (n=20 dyads) in a small randomized controlled trial. Primary outcomes will include objective sleep efficiency and total wake time measured by actigraphy for AD patients and subjective sleep measured by the Pittsburgh Sleep Quality Index for caregivers. A unique aspect of the proposed study is that the program is tailored to address sleep problems of both patients and caregivers, and includes upstream biomarkers to evaluate a key mechanism of intervention benefits that can be further explored in future research.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 1, 2023
• Est. primary completion date: January 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria for Alzheimer's disease (AD) patients:

• AD diagnosis OR probable or possible AD as documented in electronic medical record, which includes Mini Mental State Exam score >12 (indicating mild to moderate severity of AD) and neuroimaging evidence

• Community-dwelling

• >1 sleep problem >3x/week on the Neuropsychiatric Inventory Nighttime Behavior Scale

• Aged >60 years

• Able to ambulate with or without assistive device

• Have an eligible caregiver (see below)

Inclusion Criteria for caregivers:

• Live with an eligible patient

• Aged >21 years

• Have regularly assisted patient with >1 of 6 basic activities of daily living (ADLs) (i.e., bathing, dressing, toileting, transfers, continence, feeding) or >1 of 8 Instrumental ADL (IADLs) (i.e., using the telephone, shopping, preparing meals, housekeeping, laundry, transportation, taking medicine, managing money) for the past 6 months

• Pittsburgh Sleep Quality Index (PSQI) total score >5

• Montreal Cognitive Assessment (MoCA) score >= 23

• Can communicate in English

Exclusion Criteria:

• If AD patient is bed bound

Related Conditions & MeSH terms

• Alzheimer Disease
• Sleep

Intervention

Behavioral:
• Behavioral sleep education
This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
• Education only
This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations

Locations

Country	Name	City	State
United States	University of California Los Angeles	Los Angeles	California
United States	Veterans Affairs Greater Los Angeles Healthcare System	North Hills	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sleep efficiency for Alzheimer's disease patients	Sleep efficiency (mean percent time asleep while in bed) will be calculated from 3 days of wrist actigraphy	3 months after the last session of the sleep intervention
Primary	Total wake time for Alzheimer's disease patients	Total wake time (mean total minutes awake from sleep onset to get up time) will be calculated from 3 days of wrist actigraphy	3 months after the last session of the sleep intervention
Primary	Sleep quality for caregivers	Total score on the Pittsburgh Sleep Quality Index will be used as a measure of sleep quality	3 months after the last session of the sleep intervention
Secondary	Cognitive function for Alzheimer's disease patients	Total score on the Alzheimer's Disease Assessment Scale-Cognitive Subscale test will be used as a measure of cognitive function	3 months after the last session of the sleep intervention
Secondary	Problematic behaviors for Alzheimer's disease patients	Total score on the Revised Memory and Behavior Problem Checklist will be used as a measure of problematic behaviors	3 months after the last session of the sleep intervention
Secondary	Depression for Alzheimer's disease patients	Total score on the Cornell Scale for Depression in Dementia will be used as a measure of depression	3 months after the last session of the sleep intervention
Secondary	Caregiver burden for caregivers	Total score on the Zarit Burden Interview will be used as a measure of caregiver burden	3 months after the last session of the sleep intervention
Secondary	Stress for caregivers	Total score on the Perceived Stress Scale will be used as a measure of stress	3 months after the last session of the sleep intervention
Secondary	Depression for caregivers	Total score on the Center for Epidemiological Study-Depression will be used as a measure of depression	3 months after the last session of the sleep intervention
Secondary	Inflammation for caregivers	Levels of C-reactive protein and gene expression of inflammation will be measured	3 months after the last session of the sleep intervention
Secondary	Quality of life for Alzheimer's disease patients	Total score on the Quality of Life-Alzheimer's Disease Scale will be used as a measure of quality of life	3 months after the last session of the sleep intervention